当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Joshua Wiedermann
Individual tools play significant places in the fight against COVID- 19 and other afflictions. Being tests, similar as RT- qPCR, have limitations including long assay time, low outturn, shy perceptivity, and sour portability. Arising biosensing technologies hold the pledge to develop tests that are rapid-fire, largely sensitive, and suitable for pointof- care testing, which could significantly grease the testing of COVID- 19. Despite that, practical operations of similar biosensors in afflictions have yet to be achieved. In this review, we consolidate the recently developed individual tools for COVID- 19 using arising biosensing technologies and bandy their operation pledge. In particular, we present nucleic acid tests and antibody tests of COVID- 19 grounded on both conventional and arising biosensing styles. We also give perspectives on the being challenges and implicit results.